Can urinary biomarkers replace cystoscopy?

[1]  M. Babjuk,et al.  An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer , 2018, World Journal of Urology.

[2]  A. Wyatt,et al.  Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer , 2018, Bladder cancer.

[3]  H. Klocker,et al.  Increased accuracy of a novel mRNA‐based urine test for bladder cancer surveillance , 2018, BJU international.

[4]  Peter G Yousef,et al.  An update on the molecular pathology of urinary bladder tumors. , 2017, Pathology, research and practice.

[5]  M. Meng,et al.  Development of a 90‐Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection , 2017, The Journal of urology.

[6]  K. Birkenkamp-Demtröder,et al.  Re: Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis. , 2019, The Journal of urology.

[7]  T. Ørntoft,et al.  Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. , 2017, European urology.

[8]  Yvonne Vergouwe,et al.  FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study , 2017, The Journal of urology.

[9]  Y. Lotan,et al.  Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study , 2017, The Journal of urology.

[10]  Maximilian Burger,et al.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. , 2017, European urology.

[11]  J. Witjes,et al.  MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER , 2016 .

[12]  N. Malats,et al.  Validation of a DNA Methylation‐Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy , 2017, The Journal of urology.

[13]  Mark Lee,et al.  Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection , 2017, Cell.

[14]  T. Brüning,et al.  Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project. , 2016, Urologic oncology.

[15]  L. Kiemeney,et al.  Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines. , 2016, Urologic oncology.

[16]  John D Seigne,et al.  Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. , 2016, The Journal of urology.

[17]  T. Ørntoft,et al.  Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. , 2016, European urology.

[18]  M. Quek,et al.  The Paris System for Reporting Urinary Cytology: The Quest to Develop a Standardized Terminology , 2016, Acta Cytologica.

[19]  C. Dinney,et al.  Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin. , 2016, European urology.

[20]  J. Witjes,et al.  Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study. , 2016, European journal of cancer.

[21]  S. Selph,et al.  Urinary Biomarkers for Diagnosis of Bladder Cancer , 2015, Annals of Internal Medicine.

[22]  Xiaodong Li,et al.  Urine BLCA-4 exerts potential role in detecting patients with bladder cancers: a pooled analysis of individual studies , 2015, Oncotarget.

[23]  J. Rao,et al.  Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence? , 2015, World Journal of Urology.

[24]  Mårten Fernö,et al.  Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease , 2015, EMBO molecular medicine.

[25]  Q. Qin,et al.  Diagnostic accuracy of cytokeratin-19 fragment (CYFRA 21–1) for bladder cancer: a systematic review and meta-analysis , 2015, Tumor Biology.

[26]  L. Kavalieris,et al.  A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma , 2015, BMC Urology.

[27]  T. Todenhöfer,et al.  Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer , 2015, BMC Cancer.

[28]  Y. Lotan,et al.  Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus , 2014, Urologia Internationalis.

[29]  J. Witjes,et al.  EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. , 2014, European urology.

[30]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. , 2013, European urology.

[31]  W. Horninger,et al.  uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma , 2013, Cancer cytopathology.

[32]  F. Moatamed,et al.  Exclusion of the uniform tetraploid cells significantly improves specificity of the urine fish assay , 2013, Diagnostic cytopathology.

[33]  M. Dalphin,et al.  A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. , 2012, The Journal of urology.

[34]  H. Khaled,et al.  Cytogenetic profile of locally advanced and metastatic Schistosoma-related bladder cancer and response to chemotherapy. , 2012, Cancer genetics.

[35]  Xifeng Wu,et al.  Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial. , 2012, The Journal of urology.

[36]  T. Todenhöfer,et al.  Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer. , 2012, Urology.

[37]  T. Ørntoft,et al.  Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts , 2010, BMC Cancer.

[38]  M. Burset,et al.  Gene Expression Signature in Urine for Diagnosing and Assessing Aggressiveness of Bladder Urothelial Carcinoma , 2010, Clinical Cancer Research.

[39]  L. Bubendorf,et al.  The prognostic value of cytology and fluorescence in situ hybridization in the follow‐up of nonmuscle‐invasive bladder cancer after intravesical Bacillus Calmette‐Guérin therapy , 2009, International journal of cancer.

[40]  Ewout W Steyerberg,et al.  Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial. , 2009, The Journal of urology.

[41]  Y. Lotan,et al.  Soluble Fas—A promising novel urinary marker for the detection of recurrent superficial bladder cancer , 2006, Cancer.

[42]  T. Gasser,et al.  Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. , 2004, The Journal of urology.

[43]  S. Hautmann,et al.  Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid–hyaluronidase and BTA‐Stat tests , 2002, Cancer.

[44]  R. Day,et al.  Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  M. Burset,et al.  Validation study of a noninvasive urine test for diagnosis and prognosis assessment of bladder cancer: evidence for improved models. , 2014, The Journal of urology.

[46]  T. Todenhöfer,et al.  Individual risk assessment in bladder cancer patients based on a multi-marker panel , 2012, Journal of Cancer Research and Clinical Oncology.

[47]  G. Mowatt,et al.  Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. , 2010, Health technology assessment.

[48]  C. Roehrborn,et al.  Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. , 2003, Urology.